BNP Paribas Financial Markets Increases Stock Position in Inogen, Inc. (NASDAQ:INGN)

BNP Paribas Financial Markets grew its position in shares of Inogen, Inc. (NASDAQ:INGN) by 13.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 42,137 shares of the medical technology company’s stock after purchasing an additional 5,131 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.18% of Inogen worth $409,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in INGN. Meeder Asset Management Inc. purchased a new position in Inogen during the 2nd quarter worth approximately $30,000. CWM LLC increased its holdings in shares of Inogen by 2,185.9% in the 2nd quarter. CWM LLC now owns 6,629 shares of the medical technology company’s stock valued at $54,000 after acquiring an additional 6,339 shares during the period. XTX Topco Ltd purchased a new stake in Inogen in the 2nd quarter valued at $178,000. Price T Rowe Associates Inc. MD boosted its stake in Inogen by 5.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,868 shares of the medical technology company’s stock worth $193,000 after purchasing an additional 1,188 shares during the period. Finally, Susquehanna Fundamental Investments LLC grew its position in Inogen by 153.1% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 25,393 shares of the medical technology company’s stock worth $206,000 after purchasing an additional 15,361 shares during the last quarter. Institutional investors and hedge funds own 89.94% of the company’s stock.

Inogen Stock Performance

Shares of Inogen stock opened at $8.96 on Friday. The company has a market cap of $213.43 million, a P/E ratio of -3.98 and a beta of 1.02. The firm has a fifty day moving average of $9.50 and a two-hundred day moving average of $9.72. Inogen, Inc. has a one year low of $5.08 and a one year high of $13.33.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on INGN. Needham & Company LLC reaffirmed a “hold” rating on shares of Inogen in a report on Friday, November 8th. StockNews.com raised Inogen from a “hold” rating to a “buy” rating in a research note on Thursday.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.